Eton Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $80.0 | $39.0 | $31.6 | $21.3 | $21.8 |
| Operating income | -$0.8 | -$2.6 | -$1.2 | -$8.3 | -$1.5 |
| Net income | -$4.6 | -$3.8 | -$0.9 | -$9.0 | -$2.0 |
| Balance Sheet | |||||
| Total debt | — | — | $5.5 | $6.6 | $7.0 |
| Cash Flow Statement | |||||
| Free cash flow | $10.2 | $0.9 | $6.8 | $4.8 | -$4.7 |
Shares outstanding 28.6M · Free float 72.4%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.